Last week, England’s National Health Service released a commissioning framework for biological medicines, including biosimilars.
Last week, England’s National Health Service (NHS) released a commissioning framework for biological medicines, including biosimilars.
The framework, authored by the NHS’ Medicines, Diagnostics, Personalized Medicine Policy Team, explains that NHS England spent £16.8 billion ($21.6 billion) on medicines from 2015 to 2016, an 8% increase in spending over the prior year. Of the top 10 medicines prescribed, 6 are biologics. Using biosimilars could save the health system £200 million to £300 million ($270 million to $404 million) per year by 2020 to 2021, and those savings could be used to fund innovative treatments or improvements in care.
The framework proposes that at least 90% of new patients be prescribed the “best value biological medicine” within 3 months of the launch of a biosimilar for a given reference product, and that 80% of existing patients be prescribed the “best value” medicine within 12 months of a biosimilar’s launch.
The authors point to the NHS’ successes with biosimilars over the past 10 years; 80% of NHS patients receiving infliximab are now treated with a biosimilar, and 58% of patients receiving etanercept are treated with a biosimilar. The cost savings achieved by the health system through using these biosimilar options total £160 million ($216 million) per year. However, uptake of biosimialrs has been uneven in England; the framework indicates that 2 NHS trusts, both located in London, had uptake levels of biosimilar infliximab of 25% and 99%. This difference in rates shows, the authors say, a “significant opportunity” to improve uptake of biosimilar medicines.
With biosimilar rituximab now available in the European Union, and with biosimilars of trastuzumab and adalimumab expected to be available in December 2017 and October 2018, respectively, “It is now important for the NHS to embed the principles of switching to the best value biological medicine into commissioning and clinical practice, if we are to [realize] the optimal rate and extent of savings associated with these medicines,” say the authors.
The framework calls upon NHS commissioners to work with relevant stakeholders, including regional pharmacists and procurement specialists, and to partner with Regional Medicines Optimisation Committees (RMOCs) across England. RMOCs will coordinate with local providers to increase the use of the best value biologics, and will ensure that plans to transition to such medicines are in place by the end of 2017.
Healthcare providers are asked to keep up to date with local policies on switching to biosimilars, and should ensure that they know what they spend on biologic treatments. Finally, the framework also has a recommendation for patients: those receiving treatment with biologics should ask their healthcare providers if there are suitable biosimilar options that they may receive for treatment.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.